Navigation Links
Jennerex and Transgene Announce Presentation of Phase 1 Data Demonstrating that JX-594 Administration Targets Tumor Vasculature
Date:4/5/2011

SAN FRANCISCO and ILLKIRCH, France, April 6, 2011 /PRNewswire/ -- Jennerex, Inc., a private clinical-stage biotherapeutics company focused on the development and commercialization of first-in-class targeted oncolytic products for cancer, and Transgene (NYSE Euronext Paris: FR0005175080), a bio-pharmaceutical company specialized in the development of immunotherapeutic products, reported interim results from Phase 1 dose-escalation clinical trials demonstrating that administration of JX-594 targets tumor vasculature. By directly targeting and replicating within tumor vasculature, JX-594 disrupts the blood supply to the solid tumors contributing to destruction of the cancer. Data were reported in a poster presentation at the 102nd Annual Meeting of the American Association for Cancer Research (AACR) in Orlando, Florida.

"In addition to targeting, infecting and destroying cancer cells and stimulating a targeted immune response against remaining cancer cells, the analysis presented at AACR demonstrates JX-594's critical third mechanism of action—the disruption of the blood supply to the tumor," said David H. Kirn, M.D., president and chief executive officer of Jennerex.  

"Importantly, these data show that both intravenous and intratumoral injection of JX-594 can effectively attack tumor vasculature. These results further demonstrate that JX-594 may have therapeutic benefit for a variety of solid tumors including liver, colorectal and other cancers," added Philippe Archinard, chairman and chief executive officer of Transgene.

Twenty three patients were enrolled in the Phase 1 dose-escalation clinical study using intravenous JX-594 to treat advanced, treatment refractory solid tumors. Tumor biopsies, evaluated through immunohistochemical analysis, showed that JX-594 given intravenously infected the vasculature of tumors causing the blood supply to the tumor to be disrupted. In addition, in another trial of patients with primary liver can
'/>"/>

SOURCE Jennerex, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Jennerex and Transgene Announce the Presentation of Positive Clinical Data of JX-594 in Patients With Liver Tumors
2. Jennerex Names Ursula Fritsch, PharmD, as Vice President, Regulatory Affairs
3. Jennerex and Transgene Announce Initiation of Clinical Trial of Intravenous JX-594 in Patients With Refractory Metastatic Colorectal Cancer
4. Jennerex Names Dr. Mark P. Backer as Senior Vice President of Technical Operations
5. Jennerex Appoints Lara Longpre to Chief Operating Officer
6. Jennerex Appoints Gregory W. Schafer as Chief Financial Officer
7. Jennerex Announces Presentations at Upcoming Conferences
8. Jennerex, Inc. Receives EMEA Orphan Drug Designation for JX-594 for the Treatment of Hepatocellular Carcinoma
9. Jennerex Therapeutic Research Collaboration With Ottawa Hospital Research Institute Selected for $10 Million Grant From Ontario Institute for Cancer Research
10. Jennerex Treats First Patients in Phase 2 JX-594 Trial for Liver Cancer
11. Jennerex Completes the Treatment of First Patient Cohort in Phase 1 Trial With Intravenous Delivery of JX-594 Oncolytic Virus
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/29/2014)... Ohio , Aug. 29, 2014  In ... how to leverage a hospital pharmacy as a strategic ... and national practice leader for Cardinal Health,s Innovation Delivery ... pharmacy care can benefit both hospitals and patients. ... is only one part of their job in a ...
(Date:8/29/2014)... MENLO PARK, Calif. , Aug. 29, 2014 ... DMPI) ("DelMar" "the Company") today announced the filing of ... recently changed its fiscal year end to June 30th ... common stock on a national securities exchange in the ... filed with the United States Securities Exchange Commission can ...
(Date:8/29/2014)... -- , Industry professionals and media ... taking place in real-time at CPhI Worldwide  ... UBM Live , announces the launch of #CPhIChat ... its kind global industry-wide Tweetchat for pharma professionals ... to stimulate conversations on key industry issues and ...
Breaking Medicine Technology:Five Ways Hospital Pharmacies Can Fulfill Their Quality Care Mission 2Five Ways Hospital Pharmacies Can Fulfill Their Quality Care Mission 3Five Ways Hospital Pharmacies Can Fulfill Their Quality Care Mission 4DelMar Pharmaceuticals Fiscal 2014 Year End Results and Summary of Recent Developments 2DelMar Pharmaceuticals Fiscal 2014 Year End Results and Summary of Recent Developments 3DelMar Pharmaceuticals Fiscal 2014 Year End Results and Summary of Recent Developments 4DelMar Pharmaceuticals Fiscal 2014 Year End Results and Summary of Recent Developments 5CPhI Worldwide to Host #CPhIChat Provoking Debate on the Future of Pharma 2CPhI Worldwide to Host #CPhIChat Provoking Debate on the Future of Pharma 3
... Jan. 25, 2012  Amorcyte, LLC, a NeoStem, Inc. ... announces the enrollment of the first patient in ... myocardial infarction. The study is a multicenter, randomized, ... and efficacy of infarct-related artery infusion of AMR-001, ...
... hosting a free webinar on the upcoming changes to the ... and is intended to address the growing number of questions ... (Logo: http://photos.prnewswire.com/prnh/20110405/NE77664LOGO ) "We,ll do ... the current status and upcoming changes, as well as insight ...
Cached Medicine Technology:Amorcyte, a NeoStem Company, Enrolls First Patient in PreSERVE Phase 2 Trial for Acute Myocardial Infarction 2Amorcyte, a NeoStem Company, Enrolls First Patient in PreSERVE Phase 2 Trial for Acute Myocardial Infarction 3Amorcyte, a NeoStem Company, Enrolls First Patient in PreSERVE Phase 2 Trial for Acute Myocardial Infarction 4FREE Webinar: Revision of the In Vitro Diagnostic Directive 2
(Date:8/30/2014)... Denver, Colorado (PRWEB) August 30, 2014 ... solution for this disorder in a new review published ... difficult condition to deal with, so there is no ... to overcome it. The Natural Vitiligo Treatment is one ... , The Natural Vitiligo Treatment promises to stop the ...
(Date:8/30/2014)... August 30, 2014 The Plastic Surgery ... New Jersey and even in the U.S. to provide ... inches off of patients’ waists with deep-tissue heating. , ... small sections, Vanquish is more inclusive to target large ... lay comfortably under panels about one inch away from ...
(Date:8/30/2014)... 30, 2014 The establishment and ... has been one of the main strategies of ... a positive impact around the world. , Architecturally ... top trained executives and trainers deliver L. Ron ... Vital statistics demonstrate that significant reduction in ...
(Date:8/30/2014)... Seniors Guide, the comprehensive guide to all things senior, has ... Dementia, and Memory Loss . , Country singer Glen Campbell, ... the Alzheimer’s, inspired Seniors Guide writers to review the trailer ... out on October 14, 2014, shows a glimpse of Glen ... – which inspires a final tour from the musician while ...
(Date:8/30/2014)... Randy Dotinga HealthDay Reporter ... five patients operated on for broken bones or other orthopedic ... study finds. Less-educated patients and patients who had ... be "doctor shoppers," said study lead author Dr. Brent Morris, ... said, the study suggests that doctors aren,t talking to one ...
Breaking Medicine News(10 mins):Health News:Natural Vitiligo Treatment Review Exposes Fast Method for Skin Repigmentation 2Health News:NJ Top Docs Presents, The Plastic Surgery Group 2Health News:Cradle of Aviation Museum Opens Its Doors to Long Island Scientologists 2Health News:Alzheimer’s Disease and Dementia Focus on Retirement Website SeniorsGuideOnline.com 2Health News:'Doctor-Shopping' for Painkillers Common After Broken-Bone Surgery, Study Finds 2Health News:'Doctor-Shopping' for Painkillers Common After Broken-Bone Surgery, Study Finds 3
... (Pink Sheets: BPYT) ("Bioponic"), an innovative provider of ... (CAM) and nutraceutical markets, announced today that it ... Financial,Communications Corporation, as its investor relations representative. ... and approximately 62% of U.S.,adults are using some ...
... disease, study finds , , THURSDAY, Oct. 4 (HealthDay News) -- ... the heart,s left main artery should take special care of ... sisters of someone with such problems are 2.5 times more ... the siblings of patients with heart disease not related to ...
... ROCKVILLE, Md., Oct. 4 EntreMed, Inc.,(Nasdaq: ... the treatment of cancer and inflammatory diseases,announced today ... Officer,will present a Company overview at the Biotechnology ... Palace Hotel, San Francisco,California, October 9-11, 2007. Mr. ...
... Oct. 4 According to the,November 2006 Rand ... alone costs about $6.4 billion a year nationally ... If another amnesty were adopted,tens of millions of ... be added within 20 years to the U.S. ...
... The National Confectioner,s,Association has noted that up to ... this in mind, Halloween is a perfect time ... children. "Since candy and Halloween go together...Consider ... can enjoy chocolate and,lollipops on occasion as long ...
... following is a,statement by Michael Bender, director of The ... Food and Drug Administration and its various,expert groups, and ... years to present a balanced and clear message in ... there is,there is enough mercury in certain fish to ...
Cached Medicine News:Health News:Bioponic Phytoceuticals Retains OTC Financial Network for Investor Relations 2Health News:Bioponic Phytoceuticals Retains OTC Financial Network for Investor Relations 3Health News:Cardiac Artery Trouble Boosts Family Heart Risk 2Health News:Cardiac Artery Trouble Boosts Family Heart Risk 3Health News:EntreMed to Present at the Bio 2007 Investor Forum 2Health News:Message for Activists at Latino National Congreso Convention: Amnesty Will Exacerbate National Problems and Turn the U.S. into Another Mexico 2Health News:Parents can Help Young Superheroes Battle Cavities on Halloween Night 2Health News:New Fish Advice Throws Baby Out With the Bath Water, Says Mercury Watchdog Group 2
... Innovators in Anesthesia and Respiratory Products, ... medical devices for Anesthesia and Respiratory professionals. ... products that enhance the clinician's ability to ... attention to the bottom line. , ...
... Innovators in Anesthesia and Respiratory Products, ... medical devices for Anesthesia and Respiratory professionals. ... products that enhance the clinician's ability to ... attention to the bottom line. , ...
... The Raindrop® medication nebulizer achieves optimum ... MMAD particle size range is 1.04-1.10 µ ... compressor or air outlet., ,As the ... gives healthcare providers the assurance of proven ...
... the need for makeshift, modified nebulizer setups ... time gathering parts when your patient is ... deliver the utmost in Heliox rescue therapy. ... fast becoming the standard of care in ...
Medicine Products: